Mini review

Implications of Gut-Brain axis in the pathogenesis of Psychiatric disorders

Kurumi Taniguchi, Yuka Ikeda, Nozomi Nagase, Ai Tsuji, Yasuko Kitagishi and Satoru Matsuda*

Department of Food Science and Nutrition, Nara Women’s University, Kita-Uoya Nishimachi, Nara 630-8506, Japan

* Correspondence: smatsuda@cc.nara-wu.ac.jp; Tel: +81742203451; Fax: +81742203451.

Abstract: Psychiatric disorders may extremely impair the quality of life with patients and are important reasons of social disability. Several data have shown that psychiatric disorders are associated with an altered composition of gut microbiota. Dietary intake could determine the microbiota, which contribute to produce various metabolites of fermentation such as short chain fatty acids. Some of the metabolites could result in epigenetic alterations leading to the disease susceptibility. Epigenetic dysfunction is in fact implicated in various psychiatric and neurologic disorders. For example, it has been shown that neuroepigenetic dysregulation occurs in psychiatric disorders including schizophrenia. Several studies have demonstrated that the intestinal microbiome may influence the function of central nervous system. Furthermore, it has been proved that the alterations in the gut microbiota-composition might affect in the bidirectional communication between gut and brain. Similarly, evidences demonstrating the association between psychiatric disorders and the gut microbiota have come from preclinical studies. It is clear that an intricate symbiotic relationship might exist between host and microbe, although the practical significance of the gut microbiota has not yet to be determined. In this review, we have summarized the function of gut microbiota in main psychiatric disorders with respect to the mental health. In addition, we would like to discuss the potential mechanisms of the disorders for the practical diagnosis and future treatment by using bioengineering of microbiota and their metabolites.

Keywords: psychiatric disorders; gut-brain axis; microbiome; short chain fatty acids; D-amino acids; reactive oxygen species
**Abbreviations:** AD: Alzheimer’s disease; ADHD: attention deficit hyperactivity disorder; ASD: autism spectrum disorder; BBB: blood brain barrier; CNS: central nervous system; DNA: deoxyribonucleic acid; GABA: gamma amino butyric acid; GI: gastrointestinal; GPR: G protein-coupled receptor; HDACs: histone deacetylases; LPS: lipopolysaccharide; ROS: reactive oxygen species; SOD: superoxide dismutase

1. **Introduction**

Psychiatric disorders such as depression, anxiety, bipolar disorder, autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) may relate to behavioral, cognitive and emotional disturbances which are eventually rooted in disordered brain function [1]. These disorders are linked to dysregulation of various neurotransmitters as well as dysfunction of neuronal networks in brain [1]. Psychiatric disorders have sometimes etiological problems with high mortality, which contributes significantly to the global burden of diseases [2]. Environmental conditions, genetic background, immune dysregulation and some infectious agents are known to be involved in the pathogenesis of these psychiatric disorders [3,4]. In particular, infections could enhance inflammatory pathways and consequently may have certain roles in the pathogenesis of psychiatric disorders [5]. Immune responses to the infection have also shown to be involved in the diseases severity and/or treatment outcomes [6]. Further understanding about the pathogenesis of psychiatric disorders would provide a promising therapeutic option in the diseases treatment [7]. Underlying pathogenesis of psychiatric disorders has yet been poorly understood [8], however, growing evidence suggests that gut microbiome in the host could play an important role in the pathogenesis [9]. This gut-brain axis contains a biochemical pathway between the gastrointestinal tract and the central nervous system (CNS) (Figure 1). Although the presence of the gut–brain axis has long been established, several recent studies suggest that gut microbiome-management for individual with psychiatric disorder has often approved promising results [10]. A functional relationship between gut microbiota and brain could play a significant role in neurological diseases and in neurodegenerative diseases [11,12]. Consistently, it has been shown that gut microbiota affects the brain function of the host behavior in rodent models [13]. In addition, trillions of microbes in the intestine have been suggested to regulate the gut-brain axis [14]. There might be several alterations in gut microbiome among psychiatric disorders in connection with the heterogeneity of neuropsychiatric disorders. In animal models, treatment with definite microorganisms in gut could improve behavioral changes [15]. It is probable that certain gut microbiota is involved in human psychiatric disorders [16]. Microbial diversity of gut might undergo substantial changes during neuropsychiatric disorders. In this review, we have summarized and discussed the gut microbiota in main neuropsychiatric disorders for the future directions of exploration.

2. **The gut-brain axis**

The gut-brain axis characterizes a set of bidirectional communication between gut and brain [17] (Figure 1). This concept includes the interplay between the neurological system and gut microbiota including microorganisms that exist in the gastrointestinal tract. The gut microbiota is affected by various host factors including nutrition, exercise, past illnesses and past use of antibiotics [18]. Studies have shown that dysbiosis of gut microbiota could exacerbate various
neuropsychiatric disorders [19], suggesting that the cross-talk of gut-brain axis may play an important role in the pathogenesis of the disorder. In addition, patients with neurological dysfunction often exhibit some of gastrointestinal signs and/or symptoms [20]. Therefore, the gut–brain axis may have a critical role in metabolism, physiology, and homoeostasis for keeping host health [21]. However, the efficacy of targeting the gut microbiota has not yet been established, and needs further investigation [21]. It has been reported that gut microbiota is associated with the pathogenesis of several mental disorders [1,9,12,14,22]. In addition, it has been suggested the association between psychological stress and dysbiosis of gut microbiota [23]. Furthermore, the effects of antidepressant may be partially reconciled by the restoration of beneficial microbiota [24]. Daily oral administration of an antidepressant fluoxetine to healthy mice significantly decreased the abundance of beneficial Lactobacillus species, suggesting that the positive effects of the fluoxetine may be caused by good alterations in the gut microbiota [25]. Similarly, treatment with another antidepressant such as lithium, aripiprazole or valproate also increases the quantity of several specific beneficial bacteria species [26]. Normal gut microbiota could protect the brain, whereas gut dysbiosis of the microbiota could facilitate the psychiatric disorders [27]. Presumably, the gut-brain axis may be significantly affected by the loss of gut neurons and production of inflammatory cytokines [27]. It has been shown that microbes in gut could stimulate afferent sensory neurons [28]. Alterations in the gut microbial composition have been correlated with altered neurotransmitter expression in the CNS pathways controlling sensory and/or motor functions [29]. Alternatively, gut microbial metabolism may provide several precursors involved in biosynthetic pathways of neurotransmitters or neuromodulators such as dopamine, serotonin, noradrenaline, glutamic acid, and gamma amino butyric acid (GABA) [30] (Figure 1).

**Figure 1.** Hypothetical schematic image of gut–brain axis crosstalk between the brain and the intestine/colon in addition to the gut-liver axis and the gut-kidney axis is shown. Note that some critical pathways such as inflammation activation pathway have been omitted for clarity. Irregular black shapes represents something harmful factors such as ROS to the organs. Stars or question marks represent something beneficial factors such as SCFAs or D-amino acids. Question marks also represent psychiatric disorders in brain. They are for example and in no particular order. Arrowhead means stimulation. Abbreviation: ROS, reactive oxygen species; SCFAs, short chain fatty acids; HDACs, histone deacetylases; GABA, gamma amino butyric acid.
3. Gut microbiota could control ROS, short-chain fatty acids, and D-amino acids in order to keep brain healthy

Diet is known to be an important regulator of gut microbiomes [31]. Consequently, the gut flora can maintain a dynamic balance with the host and can play a unique role in host functional activities such as nutritional metabolism and host immunity [32]. In addition, the gut microbiota is involved in a wide variety of physiological features and interplay of the gut microbiota and cognition has been under focus of recent researches [33]. In this regards, disturbance of the gut microbiota might lead to the occurrence of physical and/or mental diseases. Several studies have highlighted the relationship among the gut microbiota and oxidative stresses [34]. In particular, reactive oxygen species (ROS) production has a defense mechanism that could provoke cytotoxicity against several pathogens and decrease the possibility of severe infections [35,36]. For example, epithelial cells may accomplish ROS production in response to several harmful bacteria [35]. However, the ROS might be rigorously controlled by the signaling process for appropriate gut immunity [37]. On the other hand, various bacterial species of microbiota may result in diminishing the ROS production in gut [38]. Microbial products could upregulate the activity of superoxide dismutase, which results in a smaller level of ROS and reduces the cellular apoptosis or cell death [39]. For example, the vanillin derivative improves the survival of lethally irradiated mice by promoting intestinal regeneration and increasing the number of surviving crypts [39]. There might be many ROS-sensitive enzymes in gut epithelium, which is affected by alterations of the redox condition in gut. It has been shown that cisplatin-induced ROS generation is responsible for the upregulation of SIRT2, a member of class III HDACs in cell-line cells, which is protecting cells from ROS-damages [40]. The SIRT2 is a critical modulator of aging and could extend life span of animals [40].

Soluble peptides and fibers which are not degraded by intestinal enzymes in the upper gut are further metabolized by the microbiota in the lower gut. Their main products are short chain fatty acids (SCFAs), including acetate, propionate, and butyrate [41]. SCFAs are fatty acids with fewer than six carbon atoms. Primary source of the SCFAs are the essential gut-microbial derived metabolites formed from dietary composites, while fermented foods themselves could be a secondary source of the SCFAs [42]. SCFAs have been shown regulatory substances with the potential to influence emotional state through the gut–brain axis [43]. In addition, SCFAs may increase the permeability of blood brain barrier (BBB), which demonstrates that SCFAs could directly control brain homeostasis [44]. Parenteral nutrition has been associated with the alteration of microbiota and/or SCFAs production, which could induce gut mucosal atrophy [45]. Certain level of SCFAs produced by the healthy gut microbiota have been shown possessing anti-inflammatory properties with the proper regulation of T cell proliferation [46]. These inhibitory effects existing in SCFAs may work at least in part via the regulation of histone deacetylases (HDACs) [47] (Figure 2).

Gut microbiota have a large genetic capacity to metabolize D-amino acids which are utilized as nutrients to support bacterial growth [48]. Many bacterial species encode specific racemases that convert L-amino acids to D-amino acids [49]. Accordingly, possible source of D-amino acids in mammals may mostly be their gut microbiota. For example, D-alanine production is associated with a relative abundance of bacterial species such as Enterococcus and Lactobacillus in the microbiota [50]. In addition, different bacterial species may produce distinct D-amino acids profiles [51]. Higher levels of D-amino acids have been actually associated to the gut microbial mass [52]. D-amino acid oxidase promotes senescence through the ROS production [53]. Conjugation
of several fatty acids to the side chains of certain D-amino acids has potential antimicrobial activities [54]. Interestingly, a cyclic peptide (-L-amino acid-D-amino acid-L-Val-D-Pro-) with an -SS- bridge has been shown a potent HDACs inhibitor [55] (Figure 2).

Figure 2. The gut microbiota could contribute to the beneficial production of the SCFAs, ROS and D-amino acids, which might work against the progression of psychiatric disorders. Several bacteria presented here are examples involved in those productions. However, the production has not yet been confirmed in clinical studies. PET-neuroimaging could characterize the dysregulation of HDACs in the brain of psychiatric disorders. Arrowhead means stimulation whereas hammerhead represents inhibition. Dashed line may represent weak or indirect effect compared to that of solid line. Note that some critical events such as immune activation and/or cytokine-induction have been omitted for clarity. Irregular black shapes represents something harmful factors such as ROS to the organs. Stars or question marks represent something beneficial factors such as SCFAs or D-amino acids. Question marks also represent psychiatric disorders in brain. Abbreviation: SCFAs, short-chain fatty acids; ROS, reactive oxygen species; HDACs, histone deacetylases.

4. Relationship between gut microbiota, SCFAs and HDACs may be involved in the pathogenesis of neuropsychiatric disorders

Interpretation of neuropsychiatric disorders is complicated due to overlapping symptoms [56]. Alzheimer’s disease (AD) is an irreversible type of dementia that causes memory and/or thinking problems, which may finally disturb activities of daily life [57]. The characteristic brain pathology includes amyloid plaque deposition and hyper-phosphorylation of tau protein in the brain-neurons of AD [58]. Recently, it has been hypothesized that AD may be associated with the dysbiosis of gut microbiota and their metabolite SCFAs, whose improvement has been demonstrated to inhibit the progression of AD [59]. In an AD model animal, for example, butyrate treatment increased spatial learning and neural plasticity [44, 60]. In Parkinson’s disease, nerves are affected by alpha-synuclein pathology [61]. Symptoms of Parkinson’s disease result to a large extent from loss of dopaminergic
neurons in the substantia nigra of midbrain [62]. SCFAs in a body differ between patients with Parkinson’s disease and age-matched controls [63]. Consequently, the reduction in SCFAs might induce alterations in the nervous system and contribute to gastrointestinal dysmotility in Parkinson’s disease [63]. Consistent with this, the applications of propionic acid mostly promote cell survival of dopaminergic cells [64]. Schizophrenia is a neuropsychiatric disorder associated with thinking disorders disturbing perception and social interaction in addition to the symptom of psychosis [65]. Recent studies have also found differences in microbiome composition of gut between healthy controls and schizophrenia patients [66]. Furthermore, SCFAs are reported to have neuroprotective effect and influence gene expression in haloperidol-induced neurite lesions in animal model of schizophrenia [67]. Depression is an unexciting-feeling disease that involves a loss of interest and a feeling of sadness in daily activities [68]. Some SCFAs have been shown considerably decreased in the depression compared to the control in mice model [69]. Instabilities in the gut-microbiota have been associated with the pathophysiology of depressive behavior [70]. The roles of gut microbiota may also be related to autism spectrum disorder [71]. Most of children with autism spectrum disorder have gastrointestinal disorders indicating a relationship between autism spectrum disorder and altered microbiota of the gut [72]. In a stool microbiome analysis, bipolar disorder patients have a decreased richness of *Firmicutes* and *Faecalibacterium* spp., which are SCFAs-producing bacteria [73]. Intermediation with *Lactobacillus* spp. and *Bifidobacterium* strains has noticeably decreased the psychiatric symptoms, in which an increase of the major SCFA acetate has been shown [74]. In mania and bipolar disorder models, rats treated with butyrate have presented decreased morbid locomotor activity [75]. In addition, it has been reported that treatment with sodium butyrate abolishes lipopolysaccharide-induced depression-like behaviors in mice [76].

SCFAs may protect several organs including brain by inhibiting HDACs [77] (Figure 2). Modulation of individual HDACs could be an important therapeutic approach for neurodevelopmental and/or psychiatric disorders [78]. For example, valproic acid, a class I HDAC inhibitor, is widely used antiseizure medications, which could increase gene expression via the inhibition of HDACs [79]. In animal models of neuropsychiatric disorder, dysregulation of gene transcription could be attributed to the epigenetic enzymes including HDACs [80]. Treatment of HDACs inhibitor sodium butyrate has increased the levels of acetylation on histone H3 enhancing conditioned taste aversion learning in rats [81]. Genetic alterations of HDAC2 may be linked to increased risk for the bipolar disorder [82]. In addition, anti-manic effects of HDAC-inhibition might be related to the function in brain [83]. HDACs inhibitor treatment may also act as a mood-stabilizing drug with effects on behaviors like mania and psychosis [84]. In an autism spectrum disorder model, butyrate treatment has increased long-term memory and histone acetylation [85]. In these ways, HDACs inhibitors could be used as an effective treatment for several psychiatric and neurological disorders [86]. Furthermore, the simultaneous inhibition of HDACs has a synergistic therapeutic effect in AD animal models [87]. Inhibition of specific HDACs would also be a targeted strategy in Parkinson's disease [88]. Studies have defined alterations in histone acetylation in the brains of Parkinson's disease patients in animal models [88,89]. Besides, α-synuclein accumulation has been related to the alterations in histone acetylation [88,89]. Therefore, pharmacological strategies aimed at modulating histone acetylation are under examination as new approaches to disease-modification in psychiatric disorders. Recent strategies for the treatment of neurodegenerative disorders have also included HDACs inhibitors [89].

An imaging study has demonstrated that microbiota-derived acetate, a SCFA, could alter hypothalamic gene expression [90]. Butyrate, a SCFA, has been shown to be associated with increased
expression of the tight junction protein occludin in the frontal cortex and hippocampus [91]. BBB permeability is associated with reduced expression of the occludin which are known to regulate barrier function in endothelial tissues [91]. These SCFAs are predominantly produced by gut microbiota fermentation, and serves as an important neuromodulator in the central nervous system. SCFAs may be an endogenous ligand for two orphan G protein-coupled receptors, GPR41 and GPR43 [92]. As mentioned above, those SCFAs act as a potent inhibitor of HDACs, which might regulate genes expression important for neuroplasticity associated with the psychiatric disorders [93]. It is possible that altered HDACs expression contributes to emotional disturbances through altered neuroplasticity. In fact, altered HDAC expression (not a HDAC-inhibition) has impacts on emotion-regulation and attention-regulation [94]. HDAC expression levels might modulate attention and emotion regulation.

5. Application to diagnostics of patient with psychiatric disorders

Due to a lack of definite treatments, the psychiatric disorders are public health concern [95]. A principal goal in basic neuroscience research is to develop knowledge and techniques that could be extended from animal model to the human brain, which might enable early detection and/or early treatment for the psychiatric disorders. In this meaning, translational tools that can visualize brain function are predominantly useful. However, visualizing brain function is a major challenge given that the human brain is difficult to examine directly. Recently, HDACs inhibitors have been developed as an imaging agent for the psychiatric disorders. In particular, positron emission tomography (PET)-neuroimaging has revealed the dysregulation of HDACs in schizophrenia [96]. The PET would be an ideal tool to measure and quantification of HDACs expression in a non-invasive way. This tool will be a critical addition to ex vivo methods to evaluate in CNS dysfunction [97]. The basis to examine the role of HDACs for using PET has been clinically provided in human cognition [96]. In addition, the development of neuronal PET tracers for the HDACs in brain would be progressing as an epigenetic brain marker [98]. It has been shown by the PET-neuroimaging that HDACs activity both of hippocampus and white matter in brain associates to the emotional alteration [99] (Figure 2).

The analysis of the SCFAs concentration could serve as an indirect way to analyze microbiota composition [100]. Beneficially, it would also be a non-invasive way to examine. Actually, SCFAs concentration of feces correlates to the severity of depressive symptoms [43,101]. In addition, the levels of fecal acetate, propionate, and butyrate in multiple sclerosis have been shown significantly lower than those in healthy controls [102]. Besides, fecal concentration of SCFAs (ex. butyrate and propionate) have been shown significantly reduced in anorexia nervosa [103]. The gut dysbiosis could take part in the anorexia nervosa neurobiology [103]. The metabolites could also increase the absorption of glucose and change the permeability of the intestinal barrier [104]. In addition, it has been shown that mix of butyrate-producing bacteria improves epithelial barrier integrity in vitro [104].

6. Perspectives and concluding remarks

Alterations of gut microbiota may modulate the gut–brain communication, which could lead to the development of neuropsychiatric disorders. Therefore, the use of compounds that improve the microbiota including prebiotics and/or probiotics appears to be a promising way to improve neuropsychiatric disorders [105]. For example, the disturbed gut microflora function and the fecal
SCFA pattern in childhood celiac disease are normalized after gluten-free diet [106]. The gluten-free diet could suppress several harmful intraluminal intestinal events [107]. There seem to be some possibilities for shaping the dysregulated gut homeostasis in individuals with celiac disease and/or neurodegeneration [108]. The growing interest in this area will lead to more insights into the precise mechanisms underlying gut–microbiome–brain communication. It will provide a new microbiome-based diagnostic and therapeutic strategies that could help to treat the neuropsychiatric disorders. Interestingly, gut microbiota transplantation has been reported to be sufficient both for the microglial activation in the brain and for the behavioral changes [109]. Of course, there should be a requirement for the concepts produced in animal models to be translated to the human in the future. An increase in the translocation of gut bacteria is detected in depression-patients, which might support the activation of immune responses [110]. Obviously, the gut microbiota could alter the function of the brain indirectly through the change of the inflammatory and/or immune conditions. Evaluation for intensive experiments should be compulsory to obtain further insights. Also, noninvasive neuroimaging should be more revolutionized for the understanding of brain function in a breathing human. Finally, long-term studies are mandatory to clarify the efficacy in the status from hatred to reconciliation of the psychiatric disorders.

Acknowledgments

This work was supported in part by the general grant from Nara Women’s University in Japan.

Conflict of interest

The authors declare no conflict of interest.

Author contributions

Conceptualization, KT and SM; original draft preparation and editing, KT, YI, NN, AT, YK and SM; visualization, KT and SM; supervision, SM. Each author (KT, YI, NN, AT, YK, SM) has participated sufficiently in this work of drafting the article and/or revising the article for the important rational content. All authors gave final approval of the version to be submitted.

References

1. Mathee K, Cickovski T, Deoraj A, et al. (2020) The gut microbiome and neuropsychiatric disorders: implications for attention deficit hyperactivity disorder (ADHD). J Med Microbiol 69: 14–24.
2. Vigo D, Thornicroft G, Atun R (2016) Estimating the true global burden of mental illness. Lancet Psychiatry 3: 171–178.
3. Os J, Kenis G, Rutten BP (2010) The environment and schizophrenia. Nature 468: 203–212.
4. Köhler-Forsberg O, Petersen L, Gasse C, et al. (2019) A nationwide study in denmark of the association between treated infections and the subsequent risk of treated mental disorders in children and adolescents. JAMA Psychiatry 76: 271–279.
5. Goldsmith DR, Rapaport MH, Miller BJ (2016) A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. *Mol Psychiatry* 21: 1696–1709.

6. Krefft M, Frydecka D, Zalsman G, et al. (2021) A pro-inflammatory phenotype is associated with behavioural traits in children with Prader-Willi syndrome. *Eur Child Adolesc Psychiatry* 30: 899–908.

7. Shahbazi R, Yasavoli-Sharahi H, Alsadi N, et al. (2020) Matar, C. Probiotics in treatment of viral respiratory infections and neuroinflammatory disorders. *Molecules* 25: 4891.

8. Barona M, Brown M, Clark C, et al. (2019) White matter alterations in anorexia nervosa: Evidence from a voxel-based meta-analysis. *Neurosci Biobehav Rev* 100: 285–295.

9. Bastiaanssen TFS and Cryan JF (2021) The microbiota-gut-brain axis in mental health and medication response: parsing directionality and causality. *Int J Neuropsychopharmacol* 24: 216–220.

10. Martins LB, Braga Tibães JR, Sanches M, et al. (2021) Nutrition-based interventions for mood disorders. *Expert Rev Neurother* 21: 303–315.

11. Cerdó T, Diéguez E, Campoy C (2020) Impact of gut microbiota on neurogenesis and neurological diseases during infancy. *Curr Opin Pharmacol* 50: 33–37.

12. Gubert C, Kong G, Renoir T, et al. (2020) Exercise, diet and stress as modulators of gut microbiota: Implications for neurodegenerative diseases. *Neurobiol Dis* 134: 104621.

13. Berding K, Vlckova K, Marx W, et al. (2021) Diet and the microbiota-gut-brain axis: sowing the seeds of good mental health. DOI: 10.1093/advances/nmaa181.

14. Rea K, Dinan TG, Cryan JF (2020) Gut microbiota: a perspective for psychiatrists. *Neuropsychobiology* 79: 50–62.

15. Zinchenko E, Navolokin N, Shirokov A, et al. (2019) Pilot study of transcranial photobiomodulation of lymphatic clearance of beta-amyloid from the mouse brain: breakthrough strategies for non-pharmacologic therapy of Alzheimer’s disease. *Biomed Opt Express* 10: 4003–4017.

16. Mishra SP, Shukla SK, Pandey BL (2014) A preliminary evaluation of comparative effectiveness of riluzole in therapeutic regimen for irritable bowel syndrome. *Asian Pac J Trop Biomed* 4: S335–S340.

17. Barberio B, Zamani M, Black CJ, et al. (2021) Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol* 6: 359–370.

18. Dinan TG and Cryan JF (2017) Gut instincts: microbiota as a key regulator of brain development, ageing and neurodegeneration. *J Physiol* 595: 489–503.

19. Wang J, Gu X, Yang J, et al. (2019) Gut microbiota dysbiosis and increased plasma LPS and TMAO levels in patients with preeclampsia. *Front Cell Infect Microbiol* 9: 409.

20. Stasi C, Caserta A, Nisita C, et al. (2019) The complex interplay between gastrointestinal and psychiatric symptoms in irritable bowel syndrome: A longitudinal assessment. *J Gastroenterol Hepatol* 34: 713–719.

21. Kelly JR, Clarke G, Cryan JF, et al. (2016) Brain-gut-microbiota axis: challenges for translation in psychiatry. *Ann Epidemiol* 26: 366–372.

22. Winter G, Hart RA, Charlesworth RPG, et al. (2018) Gut microbiome and depression: what we know and what we need to know. *Rev Neurosci* 29: 629–643.
23. Zheng P, Zeng B, Zhou C, et al. (2016) Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host's metabolism. *Mol Psychiatry* 21: 786–796.
24. Yang C, Qu Y, Fujita Y, et al. (2017) Possible role of the gut microbiota-brain axis in the antidepressant effects of (R)-ketamine in a social defeat stress model. *Transl Psychiatry* 7: 1294.
25. Lyte M, Daniels KM, Schmitz-Esser S (2019) Fluoxetine-induced alteration of murine gut microbial community structure: evidence for a microbial endocrinology-based mechanism of action responsible for fluoxetine-induced side effects. *Peer J* 7: e6199.
26. Saini A, Ardine M, Berruti A (2008) Major depressive disorder. *N Engl J Med* 358: 1868–1869.
27. Arneth BM (2018) Gut-brain axis biochemical signalling from the gastrointestinal tract to the central nervous system: gut dysbiosis and altered brain function. *Postgrad Med J* 94: 446–452.
28. Borre YE, O'Keeffe GW, Clarke G, et al. (2014) Microbiota and neurodevelopmental windows: implications for brain disorders. *Trends Mol Med* 20: 509–518.
29. Barbara G, Stanghellini V, Brandi G, et al. (2005) Interactions between commensal bacteria and gut sensorimotor function in health and disease. *Am J Gastroenterol* 100: 2560–2568.
30. Strandwitz P (2018) Neurotransmitter modulation by the gut microbiota. *Brain Res* 1693: 128–133.
31. Sivamaruthi BS, Suganthi N, Kesika P, et al. (2020) The role of microbiome, dietary supplements, and probiotics in autism spectrum disorder. *Int J Environ Res Public Health* 17: 2647.
32. Song Q, Wang Y, Huang L, et al. (2021) Review of the relationships among polysaccharides, gut microbiota, and human health. *Food Res Int* 140: 109858.
33. Salami M (2021) Interplay of good bacteria and central nervous system: cognitive aspects and mechanistic considerations. *Front Neurosci* 15: 613120.
34. Niederseer D, Wernly B, Aigner E, et al. (2021) NAFLD and cardiovascular diseases: epidemiological, mechanistic and therapeutic considerations. *J Clin Med* 10: 467.
35. Burgueño JF, Fritsch J, Santander AM, et al. (2019) Intestinal epithelial cells respond to chronic inflammation and dysbiosis by synthesizing H2O2. *Front Physiol* 10: 1484.
36. Belizário JE, Faintuch J, Garay-Malpartida M (2018) Gut microbiome dysbiosis and immunometabolism: New frontiers for treatment of metabolic diseases. *Mediators Inflamm* 2018: 2037838.
37. Andreyev AY, Kushnareva YE, Starkova NN, et al. (2020) Metabolic ROS signaling: to immunity and beyond. *Biochemie* 85: 1600–1667.
38. Saint-Georges-Chaumet Y, Attaf D, Pelletier E, et al. (2015) Targeting microbiota-mitochondria inter-talk: Microbiota control mitochondria metabolism. *Cell Mol Biol* 61: 121–124.
39. Li M, Gu MM, Lang Y, et al. (2019) The vanillin derivative VND3207 protects intestine against radiation injury by modulating p53/NOXA signaling pathway and restoring the balance of gut microbiota. *Free Radiol Biol Med* 145: 223–236.
40. Wang W, Im J, Kim S, et al. (2020) ROS-induced SIRT2 upregulation contributes to cisplatin sensitivity in ovarian cancer. *Antioxidants* 9: 1137.
41. Muralitharan RR and Marques FZ (2021) Diet-related gut microbial metabolites and sensing in hypertension. *J Hum Hypertens* 35: 162–169.
42. Zhou Y, Jiang Q, Zhao S, et al. (2019) Impact of buckwheat fermented milk combined with high-fat diet on rats’ gut microbiota and short-chain fatty acids. *J Food Sci* 84: 3833–3842.
43. Skonieczna-Żydecka K, Grochans E, Maciejewska D, et al. (2018) Short chain fatty acids profile is changed in Polish depressive women. *Nutrients* 10: 1939.
44. Hu L, Zhu S, Peng X, et al. (2020) High salt elicits brain inflammation and cognitive dysfunction, accompanied by alternations in the gut microbiota and decreased SCFA production. *J Alzheimers Dis* 77: 629–640.
45. Luceri C, Femia AP, Fazi M, et al. (2016) Effect of butyrate enemas on gene expression profiles and endoscopic/histopathological scores of diverted colorectal mucosa: A randomized trial. *Dig Liver Dis* 48: 27–33.
46. Häselbarth L, Ouwens DM, Teichwedye N, et al. (2016) The small chain fatty acid butyrate antagonizes the TCR-stimulation-induced metabolic shift in murine epidermal gamma delta T cells. *EXCLI J* 19: 334–350.
47. Haase S, Haghikia A, Wilck N, et al. (2018) Impacts of microbiome metabolites on immune regulation and autoimmunity. *Immunology* 154: 230–238.
48. Macfarlane GT and Macfarlane S (2012) Bacteria, colonic fermentation, and gastrointestinal health. *J AOAC Int* 95: 50–60.
49. Ray S, Das S, Panda PK, et al. (2018) Identification of a new alanine racemase in Salmonella Enteritidis and its contribution to pathogenesis. *Gut Pathog* 10: 30.
50. Gilmore MS, Skaugen M, Nes I (1996) Enterococcus faecalis cytolysin and lactocin S of Lactobacillus sake.* Antonie Van Leeuwenhoek* 69: 129–138.
51. Pidgeon SE, Fura JM, Leon W, et al. (2015) Metabolic profiling of bacteria by unnatural C-terminated d-Amino Acids. *Angew Chem* 127: 6256–6260.
52. Sasabe J, Miyoshi Y, Rakoff-Nahoum S, et al. (2016) Interplay between microbial d-amino acids and host d-amino acid oxidase modifies murine mucosal defence and gut microbiota. *Nat Microbiol* 1: 16125.
53. Nagano T, Yamao S, Terachi A, et al. (2019) d-amino acid oxidase promotes cellular senescence via the production of reactive oxygen species. *Life Sci Alliance* 2: e201800045.
54. Zhong C, Zhu N, Zhu Y, et al. (2020) Antimicrobial peptides conjugated with fatty acids on the side chain of D-amino acid promises antimicrobial potency against multidrug-resistant bacteria. *Eur J Pharm Sci* 141: 105123.
55. Arai T, Ashrafual Hoque M, Nishino N, et al. (2013) Cyclic tetrapeptides with -SS- bridging between amino acid side chains for potent histone deacetylases’ inhibition. *Amino Acids* 45: 835–843.
56. Hergueta T and Weiller E (2013) Evaluating depressive symptoms in hypomanic and manic episodes using a structured diagnostic tool: validation of a new Mini International Neuropsychiatric Interview (M.I.N.I.) module for the DSM-5 ‘With Mixed Features’ specifier. *Int J Bipolar Disord* 1: 21.
57. Ryu JC, Zimmer ER, Rosa-Neto P, et al. (2019) Consequences of metabolic disruption in Alzheimer’s disease pathology. *Neurotherapeutics* 16: 600–610.
58. Laversenne V, Nazeeruddin S, Källstig EC, et al. (2020) Anti-Aβ antibodies bound to neuritic plaques enhance microglia activity and mitigate tau pathology. *Acta Neuropathol Commun* 8: 198.
59. Guo LX, Tong Y, Wang J, et al. (2020) Determination and comparison of short-chain fatty acids in serum and colon content samples: Alzheimer’s disease rat as a case study. *Molecules* 25: 5739.
60. Liu H, Zhang JJ, Li X, et al. (2015) Post-occlusion administration of sodium butyrate attenuates cognitive impairment in a rat model of chronic cerebral hypoperfusion. *Pharmacol Biochem Behav* 135: 53–59.

61. Infante R, Scaglione C, Incensi A, et al. (2020) Longitudinal skin biopsy study of phosphorylated alpha-synuclein in a patient with Parkinson disease and orthostatic hypotension. *J Neuropathol Exp Neurol* 79: 813–816.

62. Mannal N, Kleiner K, Fauler M, et al. (2021) Multi-electrode array analysis identifies complex dopamine responses and glucose sensing properties of substantia nigra neurons in mouse brain slices. *Front Synaptic Neurosci* 13: 635050.

63. Unger MM, Spiegel J, Dillmann KU, et al. (2016) Short chain fatty acids and gut microbiota differ between patients with Parkinson’s disease and age-matched controls. *Parkinsonism Relat Disord* 32: 66–72.

64. Ostendorf F, Metzdorf J, Gold R, et al. (2020) Propionic acid and fasudil as treatment against rotenone toxicity in an in vitro model of Parkinson’s disease. *Molecules* 25: 2502.

65. Ostendorf F, Metzdorf J, Gold R, et al. (2020) Differential effects of Δ9-tetrahydrocannabinol dosing on correlates of schizophrenia in the sub-chronic PCP rat model. *PLoS One* 15: e0230238.

66. Gubert C, Kong G, Uzungil V, et al. (2020) Microbiome profiling reveals gut dysbiosis in the metabotropic glutamate receptor 5 knockout mouse model of schizophrenia. *Front Cell Dev Biol* 8: 582320.

67. Hu M, Zheng P, Xie Y, et al. (2018) Propionate protects haloperidol-induced neurite lesions mediated by neuropeptide Y. *Front Neurosci* 12: 743.

68. Girardi Paskulin LM, Kottwitz Bierhals CCB, Oliveira Dos Santos N, et al. (2017) Depressive symptoms of the elderly people and caregiver’s burden in home care. *Invest Educ Enferm* 35: 210–220.

69. Wu M, Tian T, Mao Q, et al. (2020) Associations between disordered gut microbiota and changes of neurotransmitters and short-chain fatty acids in depressed mice. *Transl Psychiatry* 10: 350.

70. Mendonça IP, Duarte-Silva E, Chaves-Filho AJM, et al. (2020) Neurobiological findings underlying depressive behavior in Parkinson’s disease: A review. *Int Immunopharmacol*. 83: 106434.

71. Maigoro AY and Lee S (2021) Gut microbiome-based analysis of lipid a biosynthesis in individuals with autism spectrum disorder: an in ailico valuation. *Nutrients* 13: 688.

72. Rose DR, Yang H, Serena G, et al. (2018) Differential immune responses and microbiota profiles in children with autism spectrum disorders and co-morbid gastrointestinal symptoms. *Brain Behav Immun* 70: 354–368.

73. Huo W, Qi P, Cui L, et al. (2020) Polysaccharide from wild morels alters the spatial structure of gut microbiota and the production of short-chain fatty acids in mice. *Biosci Microbiota Food Health* 39: 219–226.

74. Dickerson FB, Stallings C, Origoni A, et al. (2014) Effect of probiotic supplementation on schizophrenia symptoms and association with gastrointestinal functioning: a randomized, placebo-controlled trial. DOI:10.4088/PCC.13m01579.

75. Varela RB, Valvassori SS, Lopes-Borges J, et al. (2015) Sodium butyrate and mood stabilizers block ouabain-induced hyperlocomotion and increase BDNF, NGF and GDNF levels in brain of Wistar rats. *J Psychiatr Res* 61: 114–121.
76. Yamawaki Y, Yoshioka N, Nozaki K, et al. (2018) Sodium butyrate abolishes lipopolysaccharide-induced depression-like behaviors and hippocampal microglial activation in mice. *Brain Res* 1680: 13–38.

77. Lee J, Venna VR, Durgan DJ, et al. (2020) Young versus aged microbiota transplants to germ-free mice: increased short-chain fatty acids and improved cognitive performance. *Gut Microbes* 12: 1814107.

78. D’Mello SR (2019) Regulation of central nervous system development by class I histone deacetylases. *Dev Neurosci* 41: 149–165.

79. Sinn DJ, Kim SJ, Chu K, et al. (2007) Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation. *Neurobiol Dis* 26: 464–472.

80. Nestler EJ, Peña CJ, Kundakovic M, et al. (2016) Epigenetic basis of mental illness. *Neuroscientist* 22: 447–463.

81. Kwon B and Houpt TA (2010) Phospho-acetylation of histone H3 in the amygdala after acute lithium chloride. *Brain Res* 1333: 36–47.

82. Xiang B, Liu K, Yu M, et al. (2018) Systematic genetic analyses of genome-wide association study data reveal an association between the key nucleosome remodeling and deacetylase complex and bipolar disorder development. *Bipolar Disord* 20: 370–380.

83. Arent CO, Valvassori SS, Fries GR, et al. (2011) Neuroanatomical profile of antimanic effects of histone deacetylases inhibitors. *Mol Neurobiol* 43: 207–214.

84. Guidotti A, Auta J, Chen Y, et al. (2011) Epigenetic GABAergic targets in schizophrenia and bipolar disorder. *Neuropharmacology* 60: 1007–1016.

85. Kramer JM (2013) Epigenetic regulation of memory: implications in human cognitive disorders. *Biomol Concepts* 4: 1–12.

86. Martínez-Pacheco H, Picazo O, López-Torres A, et al. (2020) Biochemical and Behavioral Characterization of IN14, a New Inhibitor of HDACs with Antidepressant-Like Properties. *Biomolecules* 10: 299.

87. Cuadrado-Tejedor M, Pérez-González M, García-Muñoz C, et al. (2019) Taking advantage of the selectivity of histone deacetylases and phosphodiesterase inhibitors to design better therapeutic strategies to treat Alzheimer’s disease. *Front Aging Neurosci* 11: 149.

88. Mazzocchi M, Collins LM, Sullivan AM, et al. (2020) The class II histone deacetylases as therapeutic targets for Parkinson’s disease. *Neuronal Signal* 4: NS20200001.

89. Marsh JL, Lukacsovich T, Thompson LM (2009) Animal models of polyglutamine diseases and therapeutic approaches. *J Biol Chem* 284: 7431–7435.

90. Frost G, Sleeth ML, Sahuri-Arisoylu M, et al. (2014) The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. *Nat Commun* 5: 3611.

91. Braniste V, Al-Asmakh M, Kowal C, et al. (2014) The gut microbiota influences blood-brain barrier permeability in mice. *Sci Transl Med* 6: 263ra158.

92. Zhou Z, Xu N, Matei N, et al. (2021) Sodium butyrate attenuated neuronal apoptosis via GPR41/Gbetagamma/Pi3K/Akt pathway after MCAO in rats. *J Cereb Blood Flow Metab* 41: 267–281.

93. Simonini MV, Camargo LM, Dong E, et al. (2006) The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. *Proc Natl Acad Sci USA* 103: 1587–1592.
94. Tseng CJ, Gilbert TM, Catanese MC, et al. (2020) In vivo human brain expression of histone deacetylases in bipolar disorder. Transl Psychiatry 10: 224.
95. Kennedy H and Montreuil TC (2021) The late positive potential as a reliable neural marker of cognitive reappraisal in children and youth: a brief review of the research literature. Front Psychol 11: 608522.
96. Gilbert TM, Zürcher NR, Wu CJ, et al. (2019) PET neuroimaging reveals histone deacetylase dysregulation in schizophrenia. J Clin Invest 129: 364–372.
97. Wang C, Schroeder FA, Hooker JM (2014) Visualizing epigenetics: current advances and advantages in HDAC PET imaging techniques. Neuroscience 264: 186–197.
98. Seo YJ, Muench L, Reid A, et al. (2013) Radionuclide labeling and evaluation of candidate radioligands for PET imaging of histone deacetylase in the brain. Bioorg Med Chem Lett 23: 6700–6705.
99. Gilbert TM, Zürcher NR, Catanese MC, et al. (2019) Neuroepigenetic signatures of age and sex in the living human brain. Nat Commun 10: 2945.
100. Omori K, Miyakawa H, Watanabe A, et al. (2021) The combined effects of magnesium oxide and inulin on intestinal microbiota and cecal short-chain fatty acids. Nutrients 13: 152.
101. Minami NS, Sousa RS, Oliveira FLC, et al. (2020) Subacute ruminal acidosis in zebu cattle: clinical and behavioral aspects. Animals 11: 21.
102. Takewaki D, Suda W, Sato W, et al. (2020) Alterations of the gut ecological and functional microenvironment in different stages of multiple sclerosis. Proc Natl Acad Sci USA 117: 22402–22412.
103. Borgo F, Riva A, Benetti A, et al. (2017) Microbiota in anorexia nervosa: The triangle between bacterial species, metabolites and psychological tests. PLoS One 12: e0179739.
104. Geirnaert A, Calatayud M, Grootaert C, et al. (2017) Butyrate-producing bacteria supplemented in vitro to Crohn’s disease patient microbiota increased butyrate production and enhanced intestinal epithelial barrier integrity. Sci Rep 7: 11450.
105. Kilincarslan S and Evrensel A (2020) The effect of fecal microbiota transplantation on psychiatric symptoms among patients with inflammatory bowel disease: an experimental study. Actas Esp Psiquiatr 48: 1–7.
106. Tjellström B, Högberg L, Stenhammar L, et al. (2013) Faecal short-chain fatty acid pattern in childhood coeliac disease is normalised after more than one year’s gluten-free diet. Microb Ecol Health Dis 24: 20905.
107. Lerner A, Freire de Carvalho J, Kotrova A, et al. (2021) Gluten-free diet can ameliorate the symptoms of non-celiac autoimmune diseases. DOI: 10.1093/nutrit/nuab039.
108. Mohan M, Okeoma CM, Sestak K (2020) Dietary gluten and neurodegeneration: a case for preclinical studies. Int J Mol Sci 21: 5407.
109. Bruce-Keller AJ, Salbaum JM, Luo M, et al. (2015) Obese-type gut microbiota induce neurobehavioral changes in the absence of obesity. Biol Psychiatry 77: 607–615.
110. Simeonova D, Ivanovska M, Murdjeva M, et al. (2018) Recognizing the leaky gut as a trans-diagnostic target for neuroimmune disorders using clinical chemistry and molecular immunology assays. Curr Top Med Chem 18: 1641–1655.

© 2021 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)